Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

regimen

ABEMLETR

Cancer Type
Breast
Regimen Category
Evidence-Informed
Funding Program
Exceptional Access Program abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to specific criteria ODB - General Benefit letrozole

Regimen Monograph

Oct 2025

Patient Info Sheet

Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.

Last Updated: July 27, 2026